PACK IN HAND · ONE-PAGE CHECK
Medicine pack check sheet
Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.
Entries stay only in this open page and are not saved or sent.
Published record starting point
- Record display name
- MIRAPEX / MIRAPEX ER
- Generic name / active ingredient
- pramipexole dihydrochloride immediate-release and extended-release tablets
- Dosage-form class
- Historical MIRAPEX immediate-release oral-tablet strengths are 0.125, 0.25, 0.5, 0.75, 1, 1.25 and 1.5 mg; MIRAPEX ER extended-release oral-tablet strengths are 0.375, 0.75, 1.5, 2.25, 3, 3.75 and 4.5 mg. Immediate-release and extended-release products have different release, labelling and use pathways and must not be self-converted, assembled, split, alternated or substituted from total milligrams.
- Route
- Oral
- Record reviewed
- 2026-09-06
Copy from the pack in hand
Source-linked reading points
- Sudden sleep can occur during daily activities without clear warning. Falling asleep while driving, eating, talking or another activity, unusual somnolence, altered awareness or accident risk requires stopping hazardous activity and prompt clinical contact; severe acute situations require local emergency help.
- Orthostatic hypotension, dizziness or fainting can occur during initiation or escalation. Older age, dehydration, antihypertensives or other sedating/hypotensive medicines requires priority fall-risk review; do not self-catch up, stop or reschedule.
- Caregivers should also watch for gambling, shopping, eating, sexual or other difficult-to-control urges, and for hallucinations, delusions, confusion or marked behavioural change. Hallucination risk is higher in older adults; this is not a moral failing and should be reported promptly with the complete medicine list.
- Pramipexole is eliminated mainly by the kidneys, so renal function affects clearance. Older people or those with changing kidney function cannot copy another person's milligrams, tablet count or frequency; the site does not generate a plan from age, creatinine or eGFR.
Reviewed presentation examples — compare every field
- 0.125 mg per tablet (pramipexole dihydrochloride monohydrate; historical label strength, not a tablet-count instruction)Pramipexole immediate-release tablet
- 0.25 mg per tablet (pramipexole dihydrochloride monohydrate; historical label strength, not a tablet-count instruction)Pramipexole immediate-release tablet
- 0.5 mg per tablet (pramipexole dihydrochloride monohydrate; historical label strength, not a tablet-count instruction)Pramipexole immediate-release tablet
- 0.75 mg per tablet (pramipexole dihydrochloride monohydrate; historical label strength, not a tablet-count instruction)Pramipexole immediate-release tablet
- 1 mg per tablet (pramipexole dihydrochloride monohydrate; historical label strength, not a tablet-count instruction)Pramipexole immediate-release tablet
- 1.5 mg per tablet (pramipexole dihydrochloride monohydrate; historical label strength, not a tablet-count instruction)Pramipexole immediate-release tablet
- 0.375 mg per tablet (pramipexole dihydrochloride monohydrate; historical label strength, not a tablet-count instruction)Pramipexole extended-release tablet
- 0.75 mg per tablet (pramipexole dihydrochloride monohydrate; historical label strength, not a tablet-count instruction)Pramipexole extended-release tablet